Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: Five‐year results of a phase I–II study and initial findings of a randomized phase III trial

Abstract

Five-year results of our phase I-II study prove that sole HDR-BT of the tumor bed with careful patient selection and adequate quality assurance is a feasible alternative to WBRT. However, long-term results of phase III trials are required to determine the equivalence of TBRT alone, compared with WBRT in the management of selected patients with early breast cancer.